This Article Full Text Full Text (PDF) All Versions of this Article: 93/6/2097    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Google Scholar Articles by Frempong, B. A. Articles by Sumner, A. E. PubMed PubMed Citation Articles by Frempong, B. A. Articles by Sumner, A. E. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Metabolic Syndrome Related Collections Lipid Cardiovascular Endocrinology Female Endocrinology Metabolism

Effect of Low-Dose Oral Contraceptives on Metabolic Risk Factors in African-American Women

Clinical Endocrinology Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1612

Address all correspondence and requests for reprints to: Anne E. Sumner, M.D., National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 9000 Rockville Pike, Building 10-CRC, Room 6-5940, MSC 1612, Bethesda, Maryland 20892. E-mail: annes{at}intra.niddk.nih.gov.

Context: The effect of oral contraceptive pill (OCP) use on cardiovascular risk in African-American women is unknown.

Objective: Our objective was to examine in African-American women the effect of OCP use on insulin resistance, glucose intolerance, and triglycerides (TGs).

Design: This was a cross-sectional study.

Setting: The study was conducted at the National Institutes of Health Clinical Research Center.

Participants: A total of 104 healthy nondiabetic African-American women [21 OCP users, 83 controls, age mean ± SD, 34.7 ± 7.6 yr, body mass index (BMI) 31 ± 8.4 kg/m²] was included in the study.

Interventions: Subjects had oral glucose tolerance tests, insulin-modified frequently sampled iv glucose tolerance tests, and fasting lipid profiles. Insulin resistance was determined by the insulin sensitivity index (S_I).

Main Outcome Measures: Insulin resistance, glucose tolerance status, and TG levels were determined.

Results: Fasting glucose did not differ between OCP users and controls (P = 0.27). In contrast, compared with controls, 2-h glucose (135 ± 23 vs.120 ± 25 mg/dl; P = 0.01) and fasting TGs (73 ± 31 vs.57 ± 27 mg/dl; P = 0.02) were higher in OCP users. OCP users tended to be more insulin resistant than controls (S_I: 2.51 ± 2.01 vs. 3.46 ± 2.09; P = 0.09). Multiple regression analysis revealed that BMI, age, and OCP use were significant determinants of 2-h glucose (adjusted R² = 0.37; P < 0.001) and TG levels (adjusted R² = 0.21; P < 0.001). As BMI was a determinant of both 2-h glucose and TGs, participants were divided into nonobese and obese groups, and the analyses repeated. Among the nonobese women, the OCP users were more insulin resistant (S_I: 2.91 ± 1.58 vs. 4.35 ± 1.88; P = 0.03) and had a higher prevalence of glucose intolerance than controls (odds ratio 5.7; 95% confidence interval 1.4–24; P = 0.01).

Conclusion: In African-American women, OCP use is associated with an increase in markers of cardiovascular risk manifested by increased insulin resistance, glucose intolerance, and elevated TGs.